Tests TRIV-573 for moderate to severe atopic dermatitis in adults
Tests whether TRIV-573 injections help adults with moderate to severe eczema.
Plain-language title generated from the registry record
Registry title: A Study Evaluating TRIV-573 in Atopic Dermatitis
Key facts
- Where
- Bay City, Boardman, Boca Raton, Camp Hill, Fountain Valley, Indianapolis, Los Angeles, Miami, Myrtle Beach, San Antonio, and Spokane, United StatesSee the 13 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07782333, who can take part
Where in United States
- Bay CityBay City, United StatesTaking people
- BoardmanBoardman, United StatesTaking people
- Boca RatonBoca Raton, United StatesTaking people
- Camp HillCamp Hill, United StatesTaking people
- Fountain ValleyFountain Valley, United StatesTaking people
- IndianapolisIndianapolis, United StatesTaking people
- Los AngelesLos Angeles, United StatesTaking people
- MiamiMiami, United StatesTaking people
- MiamiMiami, United StatesTaking people
- Myrtle BeachMyrtle Beach, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- SpokaneSpokane, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Triveni Bio
- Trial code
- NCT07782333
- Record updated
- 28 October 2026
- Original description
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.Read full original descriptionShow less
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants With Moderate to Severe Atopic Dermatitis
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.
Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo).
The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.
Inclusion: Has Atopic Dermatitis; Has moderate to severe, active and symptomatic atopic dermatitis.
Exclusion: Use of prohibited medications within stated washout periods; Severe or uncontrolled medical conditions.